Person:
Sarosiek, Kristopher

Loading...
Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Sarosiek

First Name

Kristopher

Name

Sarosiek, Kristopher

Search Results

Now showing 1 - 2 of 2
  • Publication
    MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
    (MyJove Corporation, 2025-02-07) Honeywell, Megan; Isidor, Marie S.; Fraser, Cameron; Sarosiek, Kristopher
  • Thumbnail Image
    Publication
    BCL-XL directly modulates RAS signalling to favour cancer cell stemness
    (Nature Publishing Group UK, 2017) Carné Trécesson, Sophie de; Souazé, Frédérique; Basseville, Agnès; Bernard, Anne-Charlotte; Pécot, Jessie; Lopez, Jonathan; Bessou, Margaux; Sarosiek, Kristopher; Letai, Anthony; Barillé-Nion, Sophie; Valo, Isabelle; Coqueret, Olivier; Guette, Catherine; Campone, Mario; Gautier, Fabien; Juin, Philippe Paul
    In tumours, accumulation of chemoresistant cells that express high levels of anti-apoptotic proteins such as BCL-XL is thought to result from the counter selection of sensitive, low expresser clones during progression and/or initial treatment. We herein show that BCL-XL expression is selectively advantageous to cancer cell populations even in the absence of pro-apoptotic pressure. In transformed human mammary epithelial cells BCL-XL favours full activation of signalling downstream of constitutively active RAS with which it interacts in a BH4-dependent manner. Comparative proteomic analysis and functional assays indicate that this is critical for RAS-induced expression of stemness regulators and maintenance of a cancer initiating cell (CIC) phenotype. Resistant cancer cells thus arise from a positive selection driven by BCL-XL modulation of RAS-induced self-renewal, and during which apoptotic resistance is not necessarily the directly selected trait.